

HPV Vaccine Session

Janet Englund, MD
Chair, ACIP HPV Vaccine Workgroup

Advisory Committee on Immunization Practices
Atlanta, GA
February 27, 2008

Recent Developments that Impact ACIP HPV Vaccine Workgroup

- ACIP HPV Vaccine WG had been preparing for a vote on bivalent HPV vaccine
- December 2007 - FDA requested more data on bivalent HPV vaccine
- Possible priority review of quadrivalent HPV vaccine in females >26 yrs

Recent Developments that Impact ACIP HPV Vaccine Workgroup: Implications

- Table discussion of recommendations for bivalent HPV vaccine and issues related to having two HPV vaccines
- Move to presentation of vaccine trial data and discussion of HPV vaccine recommendations for 'older women'

Projected Dates for ACIP Votes Revised Plan

| Possible Dates | Vote |
|-----------------------|----------------------------------|
| Feb 2008 | - |
| June/Oct 2008 | Quadrivalent - females 27-45 yrs |
| Oct 2008/Feb 2009 | Bivalent - females |
| 2009 | Quadrivalent - Males |

ACIP HPV Vaccine WG Activities: Recommendations for Women >26 years

- ~Bimonthly conference calls to review data
 - Quadrivalent HPV vaccine in adult women – Haupt (Merck)
 - Epidemiology of HPV in 'older women' – Winer (U Washington)
 - Sexual behavior in the US – Leichliter (CDC)
 - Cost effectiveness – Goldie (Harvard)
 - Natural Hx of HPV – Schiffman and Rodriguez (NCI)
- Discussion of recommendation options

Outline of HPV Session

- Bivalent vaccine: update
- Quadrivalent vaccine: End-of-study results and Adult Women
- Epidemiology of HPV as it relates to older women
- Overview of cost effectiveness analyses
- Considerations for ACIP